Background:

Pranoprofen is a non-steroidal anti-inflammatory drug used in ophthalmology. Target: PGE2Pranoprofen 0.1% was found to be as effective as diclofenac sodium 0.1% in reducing inflammation and pain after strabismus surgery. Pranoprofen could be used as a safe and effective anti-inflammatory alternative for the treatment of inflammation following strabismus surgery [1]. pranoprofen has efficacy equivalent to a moderate-potency corticosteroid with a better safety profile. It should be considered for the treatment of chronic conjunctivitis of presumed nonbacterial origin [2]. Pranoprofen inhibited ER stress-induced glucose regulated protein 78 (GRP78) expression, an ER-localized molecular chaperon. Moreover, pranoprofen inhibited ER stress-induced CCAAT/enhancer-binding protein homologous protein (CHOP) expression, an apoptotic transcription factor. the inhibitory effect of pranoprofen on ER stress-related genes (GRP78 and CHOP) would be mediated through the inhibition of XBP-1 splicing [3].

参考文献:
[1]. Akyol-Salman, I., D. Lece-Sertoz, and O. Baykal, Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery. J Ocul Pharmacol Ther, 2007. 23(3): p. 280-3.
[2]. Notivol, R., M. Martinez, and M.V. Bergamini, Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group. Am J Ophthalmol, 1994. 117(5): p. 651-6.
[3]. Hosoi, T., et al., Effect of pranoprofen on endoplasmic reticulum stress in the primary cultured glial cells. Neurochem Int, 2009. 54(1): p. 1-6.